AstraZeneca Pharma India receives permission for Dapagliflozin tablets

AstraZeneca Pharma India Limited has received an Import and Market permission in Form CT-20 (Subsequent New Drug Approval) from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India for Dapagliflozin (Forxiga®) tablets of 10 mg - additional indication.

Through this approval, the Company is permitted to deal in Dapagliflozin (Forxiga®) tablets of 10 mg in additional / expanded indication "to reduce the risk of sustained eGFR and kidney disease, cardiovascular death and hospitalization for heart failure in adult with chronic kidney disease at risk of progression" with condition that:- it is indicated in adults for the treatment of patients of chronic kidney disease (CKD) up to eGFR of greater than or equal to 25ml/min/1.73m2. Below this, initiation of the treatment is not recommended however the patients may continue 10mg orally once daily to reduce the risk of eGFR decline, ESKD, CV death and hHF.

The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga®) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 3357.25 as compared to the previous close of Rs. 3361.55. The total number of shares traded during the day was 324 in over 150 trades.

The stock hit an intraday high of Rs. 3377.35 and intraday low of 3290.60. The net turnover during the day was Rs. 1087671.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 Pharmaceuticals Permission CDSCO Dapagliflozin Forxiga